

# Anand Gaurav

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7678631/publications.pdf>

Version: 2024-02-01

29  
papers

226  
citations

1162889

8  
h-index

1199470

12  
g-index

30  
all docs

30  
docs citations

30  
times ranked

273  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system. <i>Molecular Diversity</i> , 2023, 27, 959-985.	2.1	11
2	In Silico Investigations on the Probable Macromolecular Drug Targets Involved in the Anti-Schizophrenia Activity of Terminalia bellerica. <i>Letters in Organic Chemistry</i> , 2022, 19, 83-92.	0.2	1
3	Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3- <i>d</i> ]pyrimidin-4-one as a phosphodiesterase 10A inhibitor. <i>RSC Advances</i> , 2022, 12, 1576-1591.	1.7	6
4	Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine Atrifil and Oshagh Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. <i>Advances in Urology</i> , 2022, 2022, 1-14.	0.6	4
5	Identification of dual inhibitor of phosphodiesterase 1B/10A using structure-based drug design approach. <i>Journal of Molecular Liquids</i> , 2021, 342, 117485.	2.3	5
6	Pharmacophore Modelling and Virtual Screening Studies for the Discovery of Potential Natural Products Based PDE1B Inhibitor Lead Compounds. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2021, 21, 195-204.	0.5	1
7	Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor. <i>Heliyon</i> , 2020, 6, e04856.	1.4	12
8	Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2404-2421.	1.0	8
9	In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes. <i>Pharmacia</i> , 2020, 67, 363-371.	0.4	14
10	Synthesis of 2- <i>H</i> -chromen-4-ylacetamides as potent acetylcholinesterase inhibitors and molecular insights into binding interactions. <i>Archiv Der Pharmazie</i> , 2019, 352, e1800310.	2.1	15
11	Polymerases of Coronaviruses. , 2019, , 271-300.		22
12	Protein-Protein Interactions of Phosphodiesterases. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 555-564.	1.0	5
13	Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening. <i>Computational Biology and Chemistry</i> , 2018, 77, 52-63.	1.1	6
14	Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 2910-2924.	2.0	14
15	Syntheses, characterization, and evaluation of novel non-carboxylic analogues of Gemfibrozil: a bioisosteric approach. <i>Journal of Chinese Pharmaceutical Sciences</i> , 2017, 26, .	0.4	0
16	Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors. <i>Iranian Journal of Pharmaceutical Research</i> , 2017, 16, 910-923.	0.3	3
17	NOS Inhibitors: Structure, Biological Activity and Mechanism of Action. <i>Current Enzyme Inhibition</i> , 2016, 12, 16-29.	0.3	1
18	In Silico Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors. <i>Advances in Bioinformatics</i> , 2015, 2015, 1-10.	5.7	13

#	ARTICLE	IF	CITATIONS
19	Pharmacophore modeling, 3DQSAR, and docking-based design of polysubstituted quinolines derivatives as inhibitors of phosphodiesterase 4, and preliminary evaluation of their anti-asthmatic potential. <i>Medicinal Chemistry Research</i> , 2014, 23, 5008-5030.	1.1	21
20	Identifying the Structural Features of Pyrazolo[4,3-c]Quinoline-3-ones as Inhibitors of Phosphodiesterase 4: An Exploratory CoMFA and CoMSIA Study. <i>Current Enzyme Inhibition</i> , 2013, 9, 106-116.	0.3	0
21	3D QSAR Pharmacophore, CoMFA and CoMSIA Based Design and Docking Studies on Phenyl Alkyl Ketones as Inhibitors of Phosphodiesterase 4. <i>Medicinal Chemistry</i> , 2012, 8, 894-912.	0.7	3
22	Quantitative structure-activity relationship and design of polysubstituted quinoline derivatives as inhibitors of phosphodiesterase 4. <i>Medicinal Chemistry Research</i> , 2012, 21, 3087-3103.	1.1	4
23	3D-QSAR studies of 4-quinolone derivatives as high-affinity ligands at the benzodiazepine site of brain GABAA receptors. <i>Medicinal Chemistry Research</i> , 2011, 20, 192-199.	1.1	7
24	Exploring the Structure Activity Relationships of Imidazole Containing Tetrahydrobenzodiazepines as Farnesyltransferase Inhibitors: A QSAR Study. <i>Letters in Drug Design and Discovery</i> , 2011, 8, 506-515.	0.4	2
25	An Overview on Synthetic Methodologies and Biological Activities of Pyrazoloquinolines. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 1194-1210.	1.1	16
26	QSAR Studies on 4-Quinolone Derivatives as High-Affinity Ligands at the Benzodiazepine Site of Brain GABAA Receptors. <i>Medicinal Chemistry</i> , 2009, 5, 353-358.	0.7	2
27	Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies. <i>Journal of Receptor, Ligand and Channel Research</i> , 0, , 27.	0.7	29
28	Computational Approaches in the Development of Phosphodiesterase Inhibitors. , 0, , .		0
29	Computational Alanine Scanning Mutagenesis: Characterizing the hotspots of ILK-Ankyrin Repeat and PINCH1 Complex. , 0, , .		1